MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Recommendation of “Hold” from Analysts

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) have been given an average rating of “Hold” by the five research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $35.00.

INKT has been the topic of a number of recent research reports. Zacks Research raised shares of MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, October 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MiNK Therapeutics in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded MiNK Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday.

MiNK Therapeutics Price Performance

MiNK Therapeutics stock opened at $11.96 on Tuesday. MiNK Therapeutics has a 12 month low of $4.56 and a 12 month high of $76.00. The company has a fifty day moving average price of $11.83 and a two-hundred day moving average price of $14.30. The company has a market cap of $56.09 million, a PE ratio of -3.95 and a beta of 0.34.

MiNK Therapeutics (NASDAQ:INKT) last issued its earnings results on Friday, November 14th. The company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.21. Equities research analysts anticipate that MiNK Therapeutics will post -2.75 earnings per share for the current year.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.